<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00672321</url>
  </required_header>
  <id_info>
    <org_study_id>LCC-MREC-07-H1010-66</org_study_id>
    <secondary_id>CDR0000587987</secondary_id>
    <nct_id>NCT00672321</nct_id>
  </id_info>
  <brief_title>Answering Questions About Vitamin D Supplementation and Sun Exposure in Patients Who Have Undergone Surgery for Stage IB, Stage II, or Stage IIIA Melanoma</brief_title>
  <official_title>Melanoma Lifestyle Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Leeds Cancer Centre at St. James's University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Gathering information about vitamin D supplementation and sun exposure in patients&#xD;
      with melanoma may help doctors learn more about the disease and find what may affect cancer&#xD;
      relapse.&#xD;
&#xD;
      PURPOSE: This clinical trial is studying vitamin D supplementation and sun exposure in&#xD;
      patients who have undergone surgery for stage IB, stage II, or stage IIIA melanoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  To examine the findings of the pilot study, that vitamin D supplementation in&#xD;
           combination with vitamin D receptor (VDR) polymorphisms protects from late relapse&#xD;
           (after 3 years) in patients who have had melanoma.&#xD;
&#xD;
        -  To investigate the effects of vitamin D supplement dosage in reducing the risk of late&#xD;
           relapse.&#xD;
&#xD;
        -  To examine if vitamin D supplementation in combination with particular VDR polymorphisms&#xD;
           protects from early relapse (before 3 years).&#xD;
&#xD;
        -  To examine if serum levels of vitamin D correlate with risk of relapse in groups of&#xD;
           patients with different VDR polymorphisms.&#xD;
&#xD;
        -  To examine the effect of vitamin supplementation and VDR status on time to relapse and&#xD;
           survival in these patients.&#xD;
&#xD;
        -  To examine other factors that may affect risk of relapse by assembling a tissue (genomic&#xD;
           DNA and serum) resource.&#xD;
&#xD;
        -  To investigate the effect of exposure to incidental drugs, such as statins, on risk of&#xD;
           relapse in these patients.&#xD;
&#xD;
      OUTLINE: Patients are stratified according to disease relapse in the past 5 years (yes vs&#xD;
      no).&#xD;
&#xD;
      Patients are asked to complete a food frequency questionnaire focusing on vitamin D and the&#xD;
      following area: supplementation of diet with vitamins/fish oil and duration of use; sun&#xD;
      exposure and sunscreen-use per decade prior to and after diagnosis. Patients are also asked&#xD;
      to provide a blood sample for serum and DNA analysis. Consenting patients are also tagged&#xD;
      with the Office of National Statistics to allow passive follow up.&#xD;
&#xD;
      Stored tissue from the patient's primary melanoma may be used to corroborate research&#xD;
      findings using immunohistochemistry or studies of gene expression, polymorphism, or mutation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2007</start_date>
  <primary_completion_date type="Anticipated">September 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <primary_outcome>
    <measure>Odds ratio (OR) for vitamin D supplementation in relapse</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>OR for vitamin D supplementation in patients with specific VDR genotypes</measure>
  </primary_outcome>
  <enrollment type="Anticipated">2774</enrollment>
  <condition>Melanoma (Skin)</condition>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>gene expression analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>mutation analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>polymorphism analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>questionnaire administration</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosed with melanoma&#xD;
&#xD;
          -  Must meet either of the following conditions:&#xD;
&#xD;
               -  Resected stage IB, II, or IIIA disease that has relapsed as either stage III or&#xD;
                  IV disease (cases)&#xD;
&#xD;
                    -  First loco regional and/or visceral relapse (with/without sentinel node&#xD;
                       biopsy)&#xD;
&#xD;
                         -  No more than 3 months since first relapse&#xD;
&#xD;
               -  Resected stage IB, II, or IIIA disease that has not relapsed for â‰¥ 5 years&#xD;
                  (controls)&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julia Newton Bishop, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Leeds Cancer Centre at St. James's University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Leeds Cancer Centre at St. James's University Hospital</name>
      <address>
        <city>Leeds</city>
        <state>England</state>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-113-206-6534</phone>
      <email>p.brunyee@leeds.ac.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2009</verification_date>
  <study_first_submitted>May 3, 2008</study_first_submitted>
  <study_first_submitted_qc>May 3, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 6, 2008</study_first_posted>
  <last_update_submitted>August 9, 2013</last_update_submitted>
  <last_update_submitted_qc>August 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 12, 2013</last_update_posted>
  <keyword>recurrent melanoma</keyword>
  <keyword>stage IB melanoma</keyword>
  <keyword>stage II melanoma</keyword>
  <keyword>stage IIIA melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

